Biopharma manufacturing ‘turbulence’ boosts inquiries for India-based providers, local CDMO execs say
27 Mar 2024
India-based CDMOs have detected an uptick in biopharma client interest in their biologics and early-phase clinical offerings – and these manufacturers are accordingly adjusting their growth strategy.
“There’s an increase in demand. There’s a lot of factors that are going on that are influencing that,” Enzene Biosciences’ CEO Himanshu Gadgil told Endpoints News in an interview. Enzene especially has seen an increase in small to midsize biopharma clients reaching out. “We will definitely be looking at being more aggressive in terms of our expansion plan,” he added.
Preview
Source: EndPoints
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
SIGN UP
LOG IN
BECOME A PREMIUM SUBSCRIBER
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
-Targets
-Drugs
-Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.